News – Brains Bioceutical

News & Features

Brains Bioceutical Corp. Is Pleased to Announce the Completion of Its US$30m Capital Raise

Explore

Brains Bioceutical Corp. is pleased to announce the completion of its US$30m Capital Raise

Explore

Brains Bioceutical Expands Industry-Leading Cannabinoid Offering with D9-THC and CBN, Unveiling New Frontiers for Drug Development

December 16, 2024

Brains Bioceutical Set to Achieve One of the World’s First CEP for Cannabidiol Certification with the European Directorate for the Quality of Medicines & Healthcare

August 21, 2024

Brains Bioceutical Corp, the Global Leader in Natural Cannabinoid APIs, Introduces Revolutionary Solid THC, Ushering in a New Era of Clinical Research

March 6, 2024

Watch on demand: DSM and Brains Bioceutical present at CT-Cann 2023 Leading Industry Session

March 9, 2023

Brains Bioceutical Expands Industry-Leading Cannabinoid Offering with D9-THC and CBN, Unveiling New Frontiers for Drug Development

December 16, 2024

Vancouver, Canada – December 12, 2024 – Brains Bioceutical Corp. (Brains Bio), a global leader in natural, GMP-compliant cannabinoid Active Pharmaceutical Ingredients (APIs), announces the

Brains Bioceutical Set to Achieve One of the World’s First CEP for Cannabidiol Certification with the European Directorate for the Quality of Medicines & Healthcare

August 21, 2024

Advancing Pharmaceutical Innovation: Brains Bioceutical’s CEP Certification will Streamline Cannabinoid Drug Development, Inspired by Jazz Pharmaceuticals’ CBD-Based Epilepsy Drug and 2024 $1.4 Billion Revenue Projection

Brains Bioceutical Corp, the Global Leader in Natural Cannabinoid APIs, Introduces Revolutionary Solid THC, Ushering in a New Era of Clinical Research

March 6, 2024

Brains Bioceutical Corp Mon, March 4, 2024 at 10:00 p.m. PST·6 min read Breaking New Ground in Cannabinoid Research: Brains Bioceutical Corp’s Solid THC Paves

Watch on demand: DSM and Brains Bioceutical present at CT-Cann 2023 Leading Industry Session

March 9, 2023

Gain valuable insights into the early-stage drug development of cannabidiol (CBD) from industry experts Terry O’Regan, President of Brains Bioceutical, and Alexandru Zabara, Innovation Manager

Brains to provide EU-GMP CBD API for Brazils first medical approved cannabis product

Explore

Jas Kalsi

An experienced Chartered Professional Accountant with over 30 years of experience in providing personal and corporate taxation, corporate restructuring, financing, public offering and human resources management services. Kalsi is the Chief Financial Officer for Brains Bioceutical Corp., a global manufacturer of naturally-sourced active pharmaceutical ingredients (APIs). In this role, Kalsi is responsible for overseeing and managing the fiscal health of the group, implementing best practices with respect to finance, accounting and internal controls, obtaining funding, providing recommendations on mergers and acquisitions and working collaboratively with the CEO and Board of Directors on strategy. In addition, Kalsi will be responsible to regulatory entities and authorities, including any security exchange commissions.

Kalsi was an audit partner at KPMG focusing on small, medium and large private, government sector and public audit clients. He was the Human Resource Manager in charge of recruiting, staff development and training, and a member of KPMG’s Professional Practice Group. Subsequent to KPMG, Kalsi was the Chief Financial Officer / Chief Executive Officer of a variety of private companies including 6.5 years with a pharmaceutical fulfillment provider and API developer.

Kalsi has a proven track record in hiring top-level senior executives, restructuring companies to minimize tax and maximize cash flows, raising financing and creating a cohesive culture.

Kalsi has a passion for wellness and has created several initiatives and partnered with several leading-edge individuals to help people create and enjoy the best versions of themselves. He sees the use cannabinoids as a major tool to facilitate one’s optimum lifestyle.

With the team and infrastructure in place, Brains Bioceutical has quickly become an industry leader in both the nutraceutical and pharmaceutical cannabinoid industries, with several clinical trials and academic studies underway evaluating the efficacy of cannabinoids to treat major diseases. Under Kalsi’s leadership, Brains Bioceutical has already established market dominance, as it is the only company in the world to sell bulk API commercially around the world, supporting both the pharmaceutical and wellness sectors. With ambitious plans to expand Brains Bioceutical into a global biotech company specializing in cannabinoid health and wellness solutions, Kalsi is pioneering a new frontier in medicinal and wellness solutions across the world.

News & Features

Brains Bioceutical Corp. Is Pleased to Announce the Completion of Its US$30m Capital Raise

Brains Bioceutical Corp. is pleased to announce the completion of its US$30m Capital Raise

Brains Bioceutical Expands Industry-Leading Cannabinoid Offering with D9-THC and CBN, Unveiling New Frontiers for Drug Development

Brains Bioceutical Set to Achieve One of the World’s First CEP for Cannabidiol Certification with the European Directorate for the Quality of Medicines & Healthcare

Brains Bioceutical Corp, the Global Leader in Natural Cannabinoid APIs, Introduces Revolutionary Solid THC, Ushering in a New Era of Clinical Research

Watch on demand: DSM and Brains Bioceutical present at CT-Cann 2023 Leading Industry Session

Brains Bioceutical Expands Industry-Leading Cannabinoid Offering with D9-THC and CBN, Unveiling New Frontiers for Drug Development

Brains Bioceutical Set to Achieve One of the World’s First CEP for Cannabidiol Certification with the European Directorate for the Quality of Medicines & Healthcare

Brains Bioceutical Corp, the Global Leader in Natural Cannabinoid APIs, Introduces Revolutionary Solid THC, Ushering in a New Era of Clinical Research

Watch on demand: DSM and Brains Bioceutical present at CT-Cann 2023 Leading Industry Session

Brains to provide EU-GMP CBD API for Brazils first medical approved cannabis product

Contact Us

General Inquiries:

Request Our Investor Deck:

News & Features

Brains Bioceutical Corp. is pleased to announce the completion of its US$30m Capital Raise

Brains to provide EU-GMP CBD API for Brazils first medical approved cannabis product

Contact Us

General Inquiries:

Request Our Investor Deck:

Jas Kalsi

Chief Financial Officer

Jennifer Archibald

Chief Financial Officer

Barinder Bhullar

Senior Vice President, Corporate Affairs

William Purves

Chief Commercial Officer

Gurdeep Bains

VP of Business Development

Jorja’s Story

A father’s journey to saving his daughter’s life

Dr. Mike Bowen

Dr. Jack Taunton

Dr. Sharon Gurm

Dr. David Putrino

Dr. Gerry Ramogida

Norma Sebestyen

Dean Billington

COO

Terry O’Regan

President

Rick Brar

CEO and Chairman